Mark Lazarev
Johns Hopkins University School of Medicine
Appearances
DateMay 9, 2023BACKGROUND: Biological treatment in inflammatory bowel disease (IBD) patients is currently hampered by high non-response rates. To enhance personalized medicine and predict response to biological therapeutics such as vedolizumab, the working mechanism should be elucidated…Presenter
Johns Hopkins University School of Medicine- DateMay 21, 2024BACKGROUND: Chronic abdominal pain is prevalent in individuals with inflammatory bowel diseases (IBD). However, the determinants and phenotypes of IBD-associated pain are not well-characterized, frustrating effective pain management and mitigation strategies…
Presenter
Speakers
Johns Hopkins University School of MedicineJohns Hopkins University School of Medicine 
DateMay 5, 2025SOCIETY: ASGEModerators
Mayo Clinic ArizonaJohns Hopkins University School of Medicine
